Ready to ex­pand, Gen­Script rais­es $224M for CD­MO fo­cused on an­ti­bod­ies, cell and gene ther­a­pies

Chi­na’s Gen­Script has brought in new in­vestors to back its bi­o­log­ics-fo­cused sub­sidiary — to the tune of $224 mil­lion.

Gen­Script, which is list­ed in Hong Kong, dis­closed the Se­ries C for Gen­Script Pro­Bio in a fil­ing. The new funds will help “build up man­u­fac­tur­ing ca­pac­i­ty, fur­ther re­search and de­vel­op­ment ca­pa­bil­i­ties and op­por­tunis­ti­cal­ly ac­quire as­sets” to de­vel­op Pro­Bio’s con­tract de­vel­op­ment and man­u­fac­tur­ing busi­ness, the moth­er com­pa­ny wrote.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN